Results of Phase III MIRASOL trial are available! Hear from Dr. Kathleen Moore, PI of GOG 3045/ENGOT-ov55 trial who presented late breaking key data findings on Sunday, June 4 at ASCO Annual Meeting.

MIRASOL is the confirmatory trial for mirvetuximab soravtansine (MIRV), which was granted FDA accelerated approval last November based on the SORAYA trial. This open-label Phase 3 trial enrolled 453 FRα-high PROC patients randomized 1:1 to MIRV (6 mg/kg AIBW q3w) or investigator’s choice chemotherapy (ICC).

Although the eligibility criteria of MIRASOL and SORAYA were similar, a notable difference was that prior bevacizumab was allowed but not required for patients in MIRASOL. In contrast, prior bevacizumab was required for patients in SORAYA.

Attended previous IGCS webinars? If you have attended IGCS webinars in the past, you may already have an IGCS account and creating a new account is not required. If unsure of your login information, you may reset your information by selecting "Forgot Password" at login or contact education@igcs.org. 

Presented by:

Kathleen N. Moore, MD, MS Director, Oklahoma TSET Phase I Program Associate Professor, Section of Gynecologic Oncology Stephenson Oklahoma Cancer Center University of Oklahoma Health Sciences Center United States